

MATERIALS LICENSE

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 37, 39, 40, 70 and 71, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

Licensee 1. St. Mary Medical Center - Hobart 2. 1500 S. Lake Park Ave. Hobart, IN 46342		In accordance with letter dated September 21, 2017.	4. Expiration Date: January 31, 2026
		3. License number: 13-03459-03 is amended in its entirety to read as follows:	5. Docket No.: 030-31379 Reference No.:
6. Byproduct, source, and/or special nuclear material	7. Chemical and/or physical form	8. Maximum amount that licensee may possess at any one time under this license	9. Authorized use
A. Any byproduct material permitted by 10 CFR 35.100	A. Any	A. As Needed	A. For use in uptake, dilution and excretion studies permitted by 10 CFR 35.100.
B. Any byproduct material permitted by 10 CFR 35.200	B. Any	B. As Needed	B. For use in imaging and localization studies permitted by 10 CFR 35.200.
C. Any byproduct material permitted by 10 CFR 35.300	C. Any	C. 500 millicuries total	C. For any use permitted by 10 CFR 35.300.
D. Any byproduct material permitted by 10 CFR 31.11	D. Prepackaged Kits	D. 3 millicuries total	D. For use in in-vitro studies.

CONDITIONS

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License Number

13-03459-03

Docket or Reference Number

030-31379

Amendment No. 32

10. A. Licensed material listed in Subitem Nos. 6.A. through 6.D. may be used or stored at the licensee's facilities located at 1500 South Lake Park Avenue, Hobart, Indiana, and 300 West 61st Avenue, Hobart, Indiana.
- B. Licensed material listed in Subitem Nos. 6.A. through 6.B may be used or stored at the licensee's facilities located at 3545 Arbors Boulevard, Portage, Indiana and 3800 St. Mary Drive, Valparaiso, Indiana.
11. The Radiation Safety Officer (RSO) for this license is Santosh K. Kar, M.S.
12. Licensed material shall only be used by, or under the supervision of:
- A. Individuals permitted to work as authorized users in accordance with 10 CFR 35.13 and 10 CFR 35.14.
- B. The following individuals are authorized users for the material and medical uses as indicated:
- | <u>Authorized User(M.D.,D.O.,etc.)</u> | <u>Material and Use</u> |
|--|--|
| Mikhail Jeha, M.D. | 10 CFR 35.100 and 35.200 |
| Jong-Yuan Kuo, M.D. | 10 CFR 35.100, 35.200, 35.300, and 31.11 |
| Abdul Kawamleh, M.D. | 10 CFR 35.100 and 35.200 |
| Kais J. Yehyaw, M.D. | 10 CFR 35.100 and 35.200 |
| Harish Shah, M.D. | 10 CFR 35.100 and 35.200 |
| Vijah P. Shah, M.D. | 10 CFR 35.100 and 35.200 |
| Thomas M. Hoess, M.D. | 10 CFR 35.100, 35.200, and 31.11 |
| Jonathon T. Lee, M.D. | 10 CFR 35.100, 35.200, and 31.11 |
| Shawn R. Kenney, M.D. | 10 CFR 35.100, 35.200, and 31.11 |
| Jeffery Jon Quackenbush, M.D. | 10 CFR 35.300 |
| Koppolu P. Sarma, M.D. | 10 CFR 35.300 (for palliative treatment of bone pain using strontium-89) |
| Charles-Lauwanga Okoro, D.O. | 10 CFR 35.200 |

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License Number
13-03459-03

Docket or Reference Number
030-31379

Amendment No. 32

Authorized User(M.D.,D.O.,etc.)

Material and Use

Anas Hakam Safadi, M.D.

10 CFR 35.200

Feng Zhang, M.D.

10 CFR 35.100 and 35.200

Mary Nicholson, M.D.

10 CFR 35.100 and 35.200

John Gustaitis, M.D.

10 CFR 35.100 and 35.200

Sorin Lazar, M.D.

10 CFR 35.200

Ramana Yedavalli, M.D.

10 CFR 35.100 and 35.200

Justin Spackey, M.D.

10 CFR 35.100 and 35.200

Thomas Shin, M.D.

10 CFR 35.100 and 35.200

A. Arif Khalil, M.D.

10 CFR 35.200

Hussam Suradi, M.D.

10 CFR 35.100 and 35.200

Jack Ziegler, M.D.

10 CFR 35.200

Cam Long Choji, D.O.

10 CFR 35.200

Samer Ajam, M.D.


10 CFR 35.200



**MATERIALS LICENSE
SUPPLEMENTARY SHEET**License Number
13-03459-03Docket or Reference Number
030-31379

Amendment No. 32

13. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. This license condition applies only to those procedures that are required to be submitted in accordance with the regulations. Additionally, this license condition does not limit the licensee's ability to make changes to the radiation protection program as provided for in 10 CFR 35.26. The U.S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.
- A. Application dated July 28, 2015 (ML15218A568)
 - B. Letter dated January 6, 2016 (ML16007A727)
 - C. Letter dated January 5, 2017 (ML17018A414)
 - D. Letter dated May 22, 2017 (ML17146B324)
 - E. Letter dated June 20, 2017 (ML17172A121)
 - F. Letter dated September 28, 2017 (ML17276B167)
 - G. Letter dated December 19, 2017 (ML17354A646)



FOR THE U.S. NUCLEAR REGULATORY COMMISSION

Date: December 21, 2017By: Jennifer L. Bishop
Jennifer L. Bishop
Region 3